IP guidance

Owner: Intellectual Property Partner (IP)
Applies to: Gene Editing target categories used in discovery prioritization
Edit & update page here
History log: This is the durable record of how this guidance evolved over time - view to see who changed what, when, and why.

Summary

This page captures the current guidance that constrains target selection and influences IP strategy. The published page reflects the latest approved view.

Current guidance (today)

Competitive Patent Update – Promoter Usage Risk

  • We’ve been notified that a competitor has been granted a patent covering a promoter sequence currently used in our vector-based cloning workflows.
  • This may introduce IP exposure for programs utilizing this construct in Gene Family D targets.
  • Regulatory and Legal teams are reviewing scope, licensing implications, and potential design-around strategies.

  • Until guidance is finalized, new experimental designs using this promoter should be paused or routed for approval.

  • Target Category A is eligible for the current filing pathway with standard documentation.
  • Target Category B requires additional evidence before filing decisions.
  • Target Category C should be treated as exploratory until updated guidance is confirmed.

Competitor Patent Filing - Regulatory Element

  • Competitor X filed on a synthetic liver-tropic enhancer improving transgene expression 3-fold in murine models
  • Potential overlap with our vector optimization program
  • Action: initiate FTO review and assess design-around options

Patent Expiration - Transformation Method

  • Core claims on high-efficiency plant transformation expiring (Q4 2026)
  • Opens opportunity for in-house use without licensing fees
  • Recommendation: evaluate pipeline acceleration post-expiry

Synthetic Promoter Platform - Competitive Threat

  • Broad claims on machine-designed minimal promoters
  • Risk of blocking claims in hematopoietic applications
  • Identified potential whitespace in inducible promoter variants

Method-of-Use Patent Risk - Cell Therapy Manufacturing

  • Method claims on cytokine cocktail ratios and perfusion schedule
  • Our current SOP overlaps in 2 of 4 key parameters
  • Next step: modify expansion timeline or validate alternative cytokine mix

Sequence-Level IP - Synthetic Biology Circuit

  • Patent covers specific recombinase-based logic circuit topology
  • Relevant to our microbial biosensor program
  • Evaluating alternative recombinase families to avoid constraint

Open questions

  • Confirm whether Category B requirements apply uniformly across indications.
  • Validate Category C guidance with updated external guidance.